Development of Biosimilars—Pharmacokinetic and Pharmacodynamic Considerations

By Wang Yow-Ming   Chow Andrew  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 46-61

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

By Mahmood Iftekhar   Green Martin D.  

Clinical Pharmacokinetics, Vol. 44, Iss. 4, 2005-01 ,pp. : 331-347

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

By Scheen André J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 6, 2014-06 ,pp. : 839-857

Informa Healthcare

Access to resources Recommend Favorite

Expression of Glutamine Synthetase and Carbamoylphosphate Synthetase I in a Bioartificial Liver: Markers for the Development of Zonation in vitro

By  

Cells Tissues Organs, Vol. 188, Iss. 3, 2008-03 ,pp. : 259-269

Karger

Access to resources Recommend Favorite

Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations

By  

Current Medicinal Chemistry, Vol. 22, Iss. 21, 2015-01 ,pp. : 2558-2579

Bentham Science Publishers

Access to resources Recommend Favorite